​
​

Adaptive Bio (ADPT) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Adaptive Bio Revenue Highlights

Latest Revenue (Y)

$170.28M

Latest Revenue (Q)

$46.44M

Main Segment (Y)

Sequencing Revenue

Main Geography (Y)

Sequencing Revenue

Adaptive Bio Revenue by Period

Adaptive Bio Revenue by Year

DateRevenueChange
2023-12-31--8.11%
2022-12-31-20.06%
2021-12-31-56.88%
2020-12-31-15.65%
2019-12-31-52.83%
2018-12-31-44.77%
2017-12-31--

Adaptive Bio generated $170.28M in revenue during NA 2023, up -8.11% compared to the previous quarter, and up 305.91% compared to the same period a year ago.

Adaptive Bio Revenue by Quarter

DateRevenueChange
2024-09-30-7.51%
2024-06-30-3.15%
2024-03-31--8.54%
2023-12-31-20.74%
2023-09-30--22.50%
2023-06-30-29.96%
2023-03-31--31.80%
2022-12-31-15.40%
2022-09-30-9.55%
2022-06-30-13.05%
2022-03-31-1.82%
2021-12-31--3.89%
2021-09-30-2.50%
2021-06-30-0.16%
2021-03-31-27.35%
2020-12-31-14.78%
2020-09-30-25.30%
2020-06-30-0.37%
2020-03-31--13.63%
2019-12-31--7.10%
2019-09-30-17.71%
2019-06-30-74.78%
2019-03-31--26.33%
2018-12-31-0.02%
2018-09-30-48.58%
2018-06-30-19.07%
2018-03-31--

Adaptive Bio generated $46.44M in revenue during Q3 2024, up 7.51% compared to the previous quarter, and up 94.91% compared to the same period a year ago.

Adaptive Bio Revenue Breakdown

Adaptive Bio Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 21Dec 20Dec 19
Sequencing Revenue---
Development Revenue Regulatory Milestones---
Development Support Revenue---
Development Revenue---

Adaptive Bio's latest annual revenue breakdown by segment (product or service), as of Dec 21: Sequencing Revenue (51.12%), Development Support Revenue (42.40%), and Development Revenue Regulatory Milestones (6.48%).

Quarterly Revenue by Product

Product/ServiceDec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
Medicare Revenue-----------
Sequencing Revenue-----------
Development Revenue-----------
Sequencing Revenue From Test Deliver-----------
Sequencing Revenue From Coverage Policy-----------

Adaptive Bio's latest quarterly revenue breakdown by segment (product or service), as of Dec 21: Medicare Revenue (100.00%).

Adaptive Bio Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 21Dec 20Dec 19
Sequencing Revenue---
Development Support Revenue---
Development Revenue Regulatory Milestones---
Development Revenue---

Adaptive Bio's latest annual revenue breakdown by geography, as of Dec 21: Sequencing Revenue (51.12%), Development Support Revenue (42.40%), and Development Revenue Regulatory Milestones (6.48%).

Quarterly Revenue by Country

CountryDec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
Medicare Revenue-----------
Development Revenue-----------
Sequencing Revenue-----------
Sequencing Revenue From Coverage Policy-----------
Sequencing Revenue From Test Deliver-----------

Adaptive Bio's latest quarterly revenue breakdown by geography, as of Dec 21: Medicare Revenue (100.00%).

Adaptive Bio Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
RPRXRoyalty Pharma--
BEAMBeam Therapeutics--
APLSApellis Pharmaceuticals--
LEGNLegend Biotech--
ADPTAdaptive Bio--
VIRVir Bio--
KRYSKrystal Biotech--
CRBUCaribou Biosciences--
VECTVectivBio--
VERVVerve Therapeutics--
IKNAIkena Oncology--
KNTEKinnate Biopharma--
CWBRCohBar--
AVROAVROBIO--
ZURAZura Bio--
ELEVElevation Oncology--
SANASana Bio--
HEPAHepion Pharmaceuticals--
ENVBEnveric Biosciences--
RPHMReneo Pharmaceuticals--

ADPT Revenue FAQ

What is Adaptive Bio’s yearly revenue?

Adaptive Bio's yearly revenue for 2023 was $170.28M, representing a decrease of -8.11% compared to 2022. The company's yearly revenue for 2022 was $185.31M, representing an increase of 20.06% compared to 2021. ADPT's yearly revenue for 2021 was $154.34M, representing an increase of 56.88% compared to 2020.

What is Adaptive Bio’s quarterly revenue?

Adaptive Bio's quarterly revenue for Q3 2024 was $46.44M, a 7.51% increase from the previous quarter (Q2 2024), and a 22.46% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $43.19M, a 3.15% increase from the previous quarter (Q1 2024), and a -11.72% decrease year-over-year (Q2 2023). ADPT's quarterly revenue for Q1 2024 was $41.87M, a -8.54% decrease from the previous quarter (Q4 2023), and a 11.23% increase year-over-year (Q1 2023).

What is Adaptive Bio’s revenue growth rate?

Adaptive Bio's revenue growth rate for the last 3 years (2021-2023) was 10.32%, and for the last 5 years (2019-2023) was 100.16%.

What are Adaptive Bio’s revenue streams?

Adaptive Bio's revenue streams in c 21 are Sequencing Revenue, Development Revenue Regulatory Milestones, and Development Support Revenue. Sequencing Revenue generated $78.9M in revenue, accounting 51.12% of the company's total revenue, up 90.39% year-over-year. Development Revenue Regulatory Milestones generated $10M in revenue, accounting 6.48% of the company's total revenue, up 300.00% year-over-year. Development Support Revenue generated $65.45M in revenue, accounting 42.40% of the company's total revenue, up 20.21% year-over-year.

What is Adaptive Bio’s main source of revenue?

For the fiscal year ending Dec 21, the largest source of revenue of Adaptive Bio was Sequencing Revenue. This segment made a revenue of $78.9M, representing 51.12% of the company's total revenue.